Login to Your Account



Fine Young Cannibal?

FREEDOM ‘titers’: United’s oral PAH win yet to be measured

By Randy Osborne
Staff Writer

Monday, December 23, 2013
regulatory.jpg

Caught off guard by the FDA’s approval – and ahead of schedule, to boot – of Orenitram (treprostinil) extended-release tablets for pulmonary arterial hypertension (PAH), United Therapeutics Corp. plans to launch the product within the next six months.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription